

**Audrey's Life Science Meeting Picks for Oct. 22, 2017 through March 2018
Complimentary Service of AudreysNetwork.com**

PBSS, Tuesday Morning, Oct. 24, 2017

PBSS-San Francisco Bay Workshop "Good Laboratory Practices (GLPs): Fundamentals, Regulatory Trends and Best Practices"

Speaker: Lisa Helmonds, Vice President, MWA Consulting, Inc.

Date and Time: Tuesday, 10/24/2017, 8:30-12:30

8:45-9 am PBSS Welcome & Workshop Overview

9-9:30 am History of GLP Regulations

9:30-9:45 am Areas Covered by GLPs

9:45-10 am Key Definitions

10-10:15 am Break & Vendor Show

10:15-11:15 am Important Aspects of GLPs

- Subpart A: General Provisions
- Subpart B: Organization and Personnel
- Subparts C & D: Facilities and Equipment
- Subpart E: Testing Facilities Operations
- Subpart F: Test and Control Articles
- Subpart G: Protocol
- Subpart J: Records and Reports
- Subpart K: Disqualification

11:15 -11:30 am FDA Actions and Misconduct

11:30-12 pm Q & A

Registration fee (US\$): Regular: \$125; Academic: \$75; For unemployed or students: \$25; For major-sponsor rep (incl lunch): \$0; For vendor-show reps: \$25; For others, details available upon online login.

Location: SF Bay Area: Foster City Crowne Plaza

Registration deadline: 10/20/2017 (it will close sooner if the seating cap is reached)

Details and registration at <http://www.pbss.org/asp/eventInfo.aspx?eID=546>

Workshop Topic

This workshop will include a discussion on the history of Good Laboratory Practices (GLP) regulations, the importance of the regulations, key definitions, areas covered by the GLPs, a review of the regulations, examples of misconduct and, potential FDA actions. After completing this workshop, participants should be able to understand the origin, purpose, and expectations of the GLP regulations.

Speaker Bio

Lisa Helmonds has over 30 years of experience in Manufacturing and Quality Assurance in the pharmaceutical, biotechnology and medical device industries. She has extensive GXP knowledge, has held positions as a manufacturing chemist and QA manager/director as an FTE and as a consultant with several startups and large companies such as Syva, Syntex, Roche Bioscience, Alza, Shire, Gilead, along with many others and she understands the challenges facing the industry. She holds a BS in Zoology and minor in Chemistry from the University of Rhode Island and an MBA from Santa Clara University. She is currently Vice President of MWA Consulting, Inc. where she provides the highest quality of consulting services to MWA clients.

support@PBSS.org

www.PBSS.org

JLABS, Tuesday Morning, Oct. 24, 2017

Topic: "Excited About Your Story: Tell it Like a TED Pro

Date and Time: Tuesday Morning, October 24, 2017

9:30am

Location: JLABS @ SSF, 329 Oyster Point Blvd, 3rd Floor, South San Francisco, CA
Fees

\$35 | General Public

\$20 | Student/Academic

Program overview

Great leaders tell great stories. Stories have the power to touch people's deepest emotions. And emotions are the wellspring of loyalty, trust, co-operation and action. You will succeed more often, more quickly and more completely as you master the power of stories. And, as a human being, you are a natural born storyteller with full access and rights to the best that story has to offer. In this excellent session, you will learn how to unleash your own innate powers and have others be "Excited About Your Story."

Details and registration at

http://r20.rs6.net/tn.jsp?f=0014Vr7KTt4HYkT3ScXChii0DLMeywI5tsIFrkMhpfXuJjexrFY8BrCk_kKNhICbbCnfqMPvnCMxDxk1rOIjtf9IfmMagWmdpvkbdIM-XnTE3uTdHIZi3uuAR91jppKvEnmh3XzmmhIYHlg0TtoT5BRGJDZO-4dbC8kb6iLGvPmpwzttgCxDrACTSf3vN0NsCYI6&c=7IK8faFTT1QFfDnYW1Mb11LS7Gp0-hKzr_4fgrwwOiV46KxBRm-4HA==&ch=oY7vJfNs5oKhHHtZVSAzOqpbDDvrpkwodW-igkScTVk8Y4RKQ0x-jw==

Topic Description

Topics covered in the session will include:

Why the ability to tell a compelling story is essential for startups

5 elements of a strategic story

Strategies for pitching in front of various audiences: clinical vs. non-clinical vs. investors

How to embed storytelling into all aspects of your business and pitches

Join John Bates, TED speaker, Leadership & Communications Coach, and storyteller extraordinaire. My, does he have some stories to tell you!

Speaker Bio

John Bates has spoken, hosted, and coached for over 30 different worldwide TED and TEDx events. His group trainings are world famous and executives from companies like Johnson & Johnson Innovation Labs, Accenture, NASA, IBM, and more, recommend him to their colleagues as the best communications and leadership trainer working today. Long ago John fell in love with the Internet the moment it dawned on him what it would do for communication. Since then he has worked with early stage companies as a Founder or early employee, has been instrumental in raising hundreds of millions of dollars in Venture Capital and has always earned the title Chief Evangelist. He Co-Founded BIGWORDS.com, a dotcom darling which ended up going bust in the dotcom bomb of 2000, and he was the first employee and is a part owner of current Internet powerhouse Goldstar.com. John is a co-author of World Class Speaking in Action, an Amazon best-seller, and loves making a difference for those who make a difference.

Bio2Device Group, Tuesday Morning, Oct. 24, 2017

Topic: "Disrupting the Standard of Care Through the Novel Combination of Wearable Devices and Data Analytics"

Speaker: Justin Cambra, Senior Director of Systems Development, iRhythm Technologies

Date and Time: Tuesday, Oct. 24, 2017, 8:30 am

Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale

There is no charge or registration required for morning meetings.

Topic Description

The talk will review how iRhythm Technologies is disrupting the standard of care in diagnosing cardiac arrhythmias through the Zio Patch, Machine-Learned Algorithms, and data analysis. It will cover successes, challenges, and lessons learned utilizing data to grow and scale the diagnostic service.

Speaker Bio

Justin Cambra serves as the Senior Director of Systems Development at iRhythm Technologies, a digital health company combining novel devices and data analysis concepts to create new approaches to cardiac rhythm monitoring. In this role, Justin oversees data science, software and systems development, software quality assurance, and project management teams within the R&D organization. Previously he served as Director of Software Engineering at ViewRay, leading treatment delivery, treatment planning, and data management initiatives for the MRIdian System, the first commercial MRI-guided radiation therapy system. Prior to that, he held a number of positions within engineering at Accuray, focusing on the advancement of treatment delivery and data management capabilities for the CyberKnife and Tomotherapy.

Radiosurgery/Radiotherapy systems. Justin has an MBA in Management from the Wharton School, University of Pennsylvania, and a B.A. from the University of California, Berkeley, in Computer Science.

Palo Alto AWIS, Wednesday Evening, October 25, 2017

Topic: Authentic Courage for Decision and Conflict Coaching - AWIS Palo Alto

Date and Time: Wednesday, Oct. 25, 2017, 7- 9 PM

7:00 - 7:25: Networking dinner

7:25 - 7:30: Announcements

7:30 - 9:00: Workshop

Location: Stanford University MSOB X303, 1265 Welch Road, 3rd Floor, Stanford, CA 94305

Fee: Palo Alto AWIS Members: \$5, Pre-registered Non-Members: \$15

Fee at Door: \$20

Details and registration at <http://www.brownpapertickets.com/event/3111674>

Topic Description

Do you want to learn Decision and Conflict Coaching tools to further your career, and balance your personal and professional priorities? Often, you know what you want to accomplish and while the path appears to be simple, somehow delivering on it seems impossibly hard. This mini-workshop will teach you specific tools used for personal decision-making - resulting in thoughtful, meaningful journeys and personally defined success.

Speaker Bio

Sonoo Thadaney is the Executive Director of the Stanford Presence Center and Program in Bedside Medicine at Stanford University. Her diverse career spans higher education academic program management, teaching & mentoring, high tech product marketing, business development, leadership development, and coaching and training in conflict resolution.

WBA, Thursday Evening, Oct. 26, 2017

Topic: "WIB-SF Leadership Programs: Building a Community of Biotech Women Leaders from Bench to Boardroom"

Date and Time: Thursday, October 26, 2017, 5:00 p.m. – 8:30 p.m. PST

Program

5:00 p.m. - 6:00 p.m. Registration and Networking

6:00 p.m. - 7:30 p.m. Panel Discussion and Q&A

7:30 p.m. - 8:30 p.m. Networking

Location: DLA Piper, 555 Mission St #2400, San Francisco 94105, United States

Contact: WIB-San Francisco Bay Area, SanFrancisco@WomenInBio.org

Pricing Information

Members: \$15

Non-Members: \$45

Students: \$15*

* - Students email SanFrancisco@WomenInBio.org to obtain the registration discount code. Please note that only 10 student discount registrations are available

Registration Deadline

October 24, 2017

Details and registration at

<http://www.womeninbio.org/events/EventDetails.aspx?id=1020321&group=>

Event Description

Strategic thinkers, decision makers, and collaborative leaders are highly valued and sought after. Women In Bio provides opportunities to develop these key skills via a variety of programs, from Young Women In Bio to Boardroom Ready programs with a vision of empowering women to own the advancement of their careers.

We will have a panel moderated by Shehnaaz Suliman (M.D., MPhil, M.B.A, Theravance) that will include the following WIB and AWIS leaders: Yasmin Chandrasekher (EWIB/ WIB-MAPs), Deborah Ovadia (WIB-MAPs), Susan Bernhard (AWIS mentor), and Jaya (Yalia) Jayalakshmi (WIB - LDL / WIB-Committees). The panel will discuss how WIB provides a framework for supporting and enabling women leaders through a few specific programs: WIB Committees, Mentors-Advisors-Peers Program (MAPs), Leaders Developing Leaders (LDL), and Boardroom Ready Program.

Join us to:

1. Learn how WIB programs can enhance your professional development throughout your career
2. Learn how Women In Bio (and similar organizations) can be a catalyst in advancing your career goals
3. Start building your professional network that includes mentors and sponsors

Walk-Ins Accepted?

Walk-ins are not accepted – be sure to register early!

When registering, members can register guests at member price.

Bio2Device Group, Tuesday Morning, Oct. 31, 2017

Topic: "Opportunities and Challenges for the Health Ecosystem in Emerging Countries"

Speaker: Bert Wank, Founder & CEO, infiniRel Corporation

Date and Time: Tuesday, Oct. 31, 2017, 8:30 am

Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale

There is no registration or fees required for morning meetings.

Topic Description

Emerging markets will power global growth over the next 20 years, a \$31 Trillion Dollar economy. Health, energy, water, are at its the foundation. An economy that is based on meeting basic needs for pregnant women and an agricultural, cash based survival, must focus on the elimination of food- and water-born illnesses, as well as rapid detection, diagnosis, and cost-efficient treatment on a low cost basis. A first hand and personal look at entrepreneurs in India, their challenges and opportunities, will highlight how an eco-system may be created that leverages the best of the West with essential frugal innovation of the East.

Speaker Bio

Bert Wank is founder and CEO of infiniRel Corporation, a Silicon Valley-based start-up that is developing patent-pending power conversion and energy storage solutions for hybrid microgrids.

In 2016 he joined Adtec Electronics Pvt. Ltd. as an Advisor on Power & Energy. He has been instrumental in redefining its business as a systems developer for rural telemedicine, integrating energy and connectivity. He received the personal blessings from Sri Sri Ravi Shankar, the founder of the Art of Living foundation, successfully soliciting four demonstration projects.

Mr. Wank brings over 24 years of experience in product development, program management, applications engineering, international and strategic marketing for power semiconductor products, signal processing platforms, and recently renewable energy systems. In 2012 he was invited to serve as an external director on the Board of Director of Pancon Corporation. His expertise spans solar, wind, biogas, and energy storage technologies, including flywheels, batteries and capacitors. As a cleantech start-up executive, Mr. Wank also volunteered as Metro Director for the Cleantech Open business accelerator in North Texas from 2013 to 2015, and was voted "Cleantech Hero" in 2013. Prior to founding infiniRel, Mr. Wank has launched 14 battery and power management semiconductor product lines at Dallas Semiconductor (acquired by Maxim), Burr-Brown (acquired by Texas Instruments), and austriamicrosystems, a European high-voltage CMOS foundry. Between 2000 and 2001, Mr. Wank also served as Expert Witness to Silicon Valley IP law firm Blakely Sokolof Taylor & Zafman, in an alleged patent infringement relating to battery management.

He holds a BSEE from Germany and an MBA in International Business from Thunderbird, Glendale, AZ. As a dual citizen of the U.S. and Germany he speaks fluent German and English, and basic Mandarin Chinese.

JLABS, Thursday Midday, Nov. 2, 2017

Topic: "Let's Talk Legal Workshop | Venture Financing: What to Expect and Strategies for Success"

Speakers: Stuart Wilks | Assistant General Counsel, Johnson & Johnson,
Steven A. Wilcox | Partner, Ropes & Gray, Brad Flint | Associate, Ropes & Gray
Date and Time: Thursday, November 2, 2017 from 10:30 AM to 1:00 PM (PDT)
Agenda:

10:30 AM - 11:00 AM | Registration & Networking

11:00 AM - 11:45 AM | Presentation

11:45 AM - 12:00 PM | Q&A

12:00 PM - 1:00 PM | Lunch and Networking

1:00 PM | Program Close

Location: JLABS @ SSF, 329 Oyster Point Blvd. Floor 3, South San Francisco, CA
94080

Ticket Information

Fees:

\$25 | General Public

\$10 | Student/Academic

\$35 | At the door

** Please note: fees do not go to the presenting lawyers, they cover only a portion of catering and event costs

Details and registration at <https://www.eventbrite.com/e/lets-talk-legal-workshop-venture-financing-what-to-expect-and-strategies-for-success-tickets-35582902419?aff=weekly>

Join us for "Let's Talk Legal I Venture Financing: What to Expect and Strategies for Success" –a workshop designed to help entrepreneurs demystify the legal landscape and fill in the blanks. The program is interactive and informal so bring your questions with you!

Program Overview

You're past the initial stages in establishing your startup company and are ready to take it to the next level - raising capital. What should you expect during a pivotal early stage company financing round and what are the strategies for ensuring you meet your objectives and protect your interests?

This practical session will focus on how to approach a venture financing round - key topics include:

Venture capital financing deal structures

Key deal terms that are commonly subject to heavy negotiation

Considerations for protecting founder interests

Strategic investors v. venture capital investors

This event is brought to you by Johnson & Johnson's law department working in close partnership with Ropes & Gray LLP, a preeminent global law firm with deep expertise in life sciences. The lawyers presenting these workshops have extensive experience working with life sciences companies ranging from very early-stage startup companies to global public companies..

Speakers' Bios

Stuart Wilks is Assistant General Counsel at Johnson & Johnson resident at the Johnson & Johnson Innovation Center in Menlo, Park California. In this role, Stuart provides general legal advice to the Innovation Center team in California, participates directly as legal counsel in Innovation Center transactions, and/or coordinates with colleagues in the Johnson & Johnson Law Department to support Innovation Center matters.

During his nearly fifteen years with Johnson & Johnson, in addition to the California Innovation Center, Stuart has supported a diverse group of Johnson & Johnson operating companies and units, such as Alza, BabyCenter, Janssen Health Innovation, Janssen Research & Development, Janssen Supply Chain, Johnson & Johnson Innovation – JJDC, Inc., Noramco, and Scios in a broad range of business and contractual matters. Prior to joining Johnson & Johnson, Stuart was corporate counsel at Scios, Inc. in Fremont, California, corporate counsel at COR Therapeutics, Inc. in South San Francisco, California and an associate in the corporate and life sciences practice groups of the Palo Alto office of Cooley LLP.

Steve Wilcox focuses his practice on mergers and acquisitions, corporate financing transactions (including public offerings and venture capital investments) and licensing and collaborations. Most of his clients are engaged in the biotech, medical device and pharmaceutical industries. In addition to transactional work, he regularly counsels companies on a range of federal securities and corporate governance matters.

Steve is a founder and former chair of the firm's life sciences practice group.

Steve has been counsel to some of the world's leading companies including Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius, Johnson & Johnson, Medtronic, Millennium, Pfizer, Schering Plough, Smith & Nephew and Takeda Pharmaceuticals. Steve has also represented medical research institutions such as Cleveland Clinic, The Massachusetts General Hospital and Rockefeller University in connection with the spin-off or commercialization of their promising technologies. Steve has represented a number of entrepreneurs and venture capitalists in the life sciences industry, and the companies they have created, including AgeneBio, Alzheon, Blossom Innovations, Eléme Medical, InfoBionic, Normoxys, Percardia, pHLIP, Inc., Point Therapeutics, Salient Surgical, Vapotherm and Verax Biomedical.

Brad Flint advises a broad range of public and private company clients on start-up and formation matters, corporate governance, debt and equity financing, mergers and acquisitions, technology licensing and transfer, collaboration arrangements, supply and distribution agreements, and other general corporate matters. Brad represents clients in a variety of industries including biotechnology, pharmaceutical, medical device, software, and technology. He also regularly represents venture capital and private equity investors in connection with portfolio company investments and acquisitions.<

Rosenman Institute Partnering Day, Wednesday, November 8, 2017

Event: Meet one-on-one with Nipro Corp., a leading Japanese medtech company

Date: Wednesday, November 8

Location: UCSF Mission Bay

Deadline to apply is 11:59 pm, Wednesday, Nov. 1

Apply at http://www.surveygizmo.com/s3/3891075/Meet-with-Nipro-at-UCSF-Mission-Bay-November-2017?mc_cid=7cec087446&mc_eid=cb4c38a44a

Event Description

Nipro Corporation is a global medical device company headquartered in Japan whose worldwide sales in 2016 exceeded \$3 billion. Nipro, a partner of the Rosenman Institute, is looking to develop and acquire innovative technologies that complement and strengthen its IP portfolio. They're interested in meeting startups in our ecosystem.

The Rosenman Institute is coordinating a partnering session on Wednesday, November 8 at UCSF Mission Bay. Space is limited. If you see an opportunity in partnering with Nipro, please apply online. The deadline is midnight on November 1.

EMBS, Wednesday Evening, Nov. 15, 2017

EMBS Chapter meeting on Wednesday, November 15, 2017, which will include an invited speaker.

Speaker: Steve Axelrod, CEO of G-Tech Medical

Follow for details at <http://www.ewh.ieee.org/r6/scv/embs>

Topic Description

Early results from proof of concept clinical trials with G-Tech Medical's "EKG for the Gut"

Brief summary: Motility, the movement through the digestive tract of what starts out as food, is usually taken for granted, until something goes wrong. There are a wide range of gastrointestinal (GI) disorders and dysfunctions that can be blamed on motility issues. G-Tech has developed electrode patches worn on the abdomen that read electrical signals emanating from the muscles of the stomach, small intestine and colon when they are active – driving motility – that are thin, wireless and non-invasive. Over the past two years G-Tech has launched clinical trials with patients recovering from abdominal surgery and with patients with Parkinson's disease. Interesting results have been obtained in these cases and also in volunteer tests, and will be described in the talk.

More details will be provided in our EMBS-SCV November announcement

PBSS Workshop, Monday, Dec. 11, 2017

Event Name: Clinical Pharmacology & Modeling Strategies for your Drug Development

Program: Fundamentals, Best Practices and Real World Applications

Speakers: David Lau (Foresee Pharmaceuticals), Geoff Banks (Nuventra), Mark Sale (Nuventra), Lauren Lohmer (Nuventra)

Date and Time: Monday, Dec. 11, 2017, 8:45-17:00

Preliminary Agenda

8:45 – 9:00 Welcome and Intro

9:00 – 10:30 – David Lau (Senior Vice President, NCE Preclinical and Clinical Development, Foresee Pharmaceuticals)

Purpose of Clin Pharm Studies in Drug Development

Type of Clin Pharm studies (SAD, MAD, BA/BE, DDI, Disease population, QT, etc)

- What are these studies
- When to do the studies
- Typical study design
- Examples

10:30 – 11:00 – Break and Vendor Presentation

11:00 – 12:30 – Geoff Banks (CEO, Nuventra)

How to Form a Clin Pharm Strategy for your NDA / BLA

- What studies you do & don't need
- "Gap analysis" in your program
- Real world examples

12:30 – 1:30 – Lunch

1:30 – 3:00 – Mark Sale (Senior Vice President, Pharmacometrics, Nuventra)

Modeling & Simulation / Population PK Fundamentals

- What is it?
- How do you do it?
- Allometric scaling
- How do you use it for safety and efficacy?

3:00 – 3:30 Break and vendor presentation

3:30 – 5:00 – Mark Sale and Lauren Lohmer (Manager, Clinical Pharmacology, Nuventra)

Using Modeling & Simulation to Avoid Clinical Trials

- Overview and case studies:
 - CQT
 - Exposure response
 - Additional DDI studies
 - Special population studies
 - Renal impairment

Location: SF Bay Area: Foster City Crowne Plaza

Registration fee (US\$): Academic: \$125; Regular: \$195; For unemployed or students: \$30;

For major-sponsor rep (incl lunch): \$0; For vendor-show rep: \$35;

Details and registration at <http://www.pbss.org/asp/EventInfo.aspx?eID=557>

Registration deadline: 12/8/2017 (it will close sooner if the seating cap is reached)

This is a friendly reminder that you have not registered for the following Workshop . If you plan to attend, please register at www.pbss.org before it is closed (it may close BEFORE the deadline if the seating capacity is reached early).

JLABS, Thursday Morning, Jan. 25, 2017

Topic: "Who's Who in 2018: A Strong Finish to 2017 Healthcare Investing?"

Speaker: Jonathan Norris | Managing Director, Silicon Valley Bank

Date and Time: Thursday, January 25, 2018 from 8:00 AM to 10:00 AM (PST)

Agenda:

8:00 AM | Registration, Breakfast & Networking

8:30 AM | Presentation - Q&A

9:30 AM | Networking

10:00 AM | Program Close

Location:

JLABS @ SSF

329 Oyster Point Blvd - 3rd Floor

South San Francisco, CA

Fees:

\$12 | General Public

\$8 | Student/Academic

\$25 | At the door

Details and registration at <https://www.eventbrite.com/e/whos-who-in-2018-a-strong-finish-to-2017-healthcare-investing-tickets-36706212269?aff=weekly>

Event Details

2017 saw a banner first half, driven in part by advancements in artificial intelligence and machine learning for healthcare applications and a surge in Series A investments. With 2017 in the review mirror, Jon Norris takes a look at – and makes sense of – the past trends to provide an informed look into 2018.

As the 2018 investment market takes shape, what can we expect for the IPO and M&A markets? Jon will share his expertise and provide insight into:

How the 2017 healthcare landscape compares to previous years

Current and total healthcare and sector investments

Which Biopharma indications attracted the most funds

Which venture firms are most active

Changes in the past crossover phenomenon

Exits: the trends in IPOs and M&A's

At the end of this talk you should be informed as to who is investing, and the type of deals and exits that are likely to be executed in 2018.

Presenter's Biography:

Jonathan Norris | Managing Director, Silicon Valley Bank

Jon Norris is a managing director for SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on direct equity co-investment and limited partnership allocations.

In addition, he has authored numerous thought leadership pieces examining the flow of capital into healthcare, including detailed analysis of venture-backed M&A and IPOs. Norris has more than thirteen years of banking experience working with life science companies and venture capital firms.

Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.

About Jon Norris spends most of his non-banking time with his family in Los Altos, attending and coaching many youth sports. An avid baseball fan, he still plays baseball in a men's baseball league in San Jose.

JLABS, Thursday Morning, Feb. 2, 2018

Event: "Meet With...Versant Ventures"

Speakers: Graham G. Walmsley | Investment Professional, Versant Ventures and Lev Osherovich | Director of Innovation Sourcing, Versant Ventures

Date and Time: Thursday, February 1, 2018 from 10:30 AM to 1:00 PM (PST)

Agenda:

10:30AM | Registration and Networking

11:00 AM | Presentation and Q&A

12:00 PM | Networking Lunch

1:00-5:15 PM | One-on-One Meeting* (30 - minute meetings)

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due January 4, 2018. [Apply Here.](#)

Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd, 3rd Floor South San Francisco, CA

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Details and registration at <https://www.eventbrite.com/e/meet-withversant-ventures-tickets-36705327623?aff=weekly>

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Apply to meet one-on-one with Graham Walmsley of Versant Ventures. Your application will be reviewed and you will be notified of acceptance on Wednesday, January 18th, 2018. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Event Details

Committed to transforming the healthcare landscape through innovation, Versant Ventures is eager to help you make an impact in healthcare. Graham Walmsley, MD, Ph.D. and Lev Osherovich, Ph.D. of Versant Ventures will be visiting JLABS @ SSF on February 1, 2018 to provide an overview of Versant's unique investment strategies and meet 1-on-1 with pre-selected companies.

*The one-on-one application process is separate from the event registration process. Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due by January 4th. Apply Here.

Program Overview:

Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs who are building the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With \$2.3 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm's founding in 1999, nearly 70 Versant companies have achieved successful acquisitions or IPOs.

Graham Walmsley, MD, Ph.D. and Lev Osherovich, Ph.D. will be in attendance to provide an overview presentation of their firm's area of interest. They will be on hand to meet with a handful of applicants 1-on-1 after the presentation. To be considered for a 1-on-1 meeting complete the information required here. Applications due by January 4, 2018.

Speakers' Biographies:

Graham G. Walmsley | Investment Professional, Versant Ventures

Graham G. Walmsley, M.D., Ph.D. is an Investment Professional at Versant Ventures focused on biotechnology and healthcare investments. Graham joined Versant after completing his training as a Physician Scientist Fellow at Stanford University School of Medicine. At Versant, Graham helped build and launch BlueRock Therapeutics, a regenerative medicine company formed in collaboration with Bayer through one of the largest series A investments (\$225M) in biotech history.

Graham received his M.D. and Ph.D. in Stem Cell Biology and Regenerative Medicine from Stanford University and earned his B.A. in Molecular and Cell Biology with summa cum laude honors from the University of California, Berkeley. He conducted his thesis work in the laboratories of Irving Weissman and Michael Longaker with a focus on regenerative medicine, stem cells, and therapeutic approaches to fibrosis. This work was featured in TIME Magazine and resulted in several patents as well as over 60 peer-reviewed publications in journals such as Science and Cell.

Lev Osherovich | Director of Innovation Sourcing, Versant Ventures

Lev Osherovich, Ph.D. is Director of Innovation Sourcing at Versant Ventures, where he focuses on early stage therapeutic investment. Lev trained in Molecular and Cell Biology at UC Berkeley (undergraduate) and in Biochemistry at UCSF, and completed postdoctoral training at University of Kent at Canterbury and UCSF. After leaving academia, he worked as a biotech industry analyst and science journalist at BioCentury and Nature Publishing Group. Since 2014, Lev has worked at Versant and its discovery engine, Inception Sciences, to evaluate academic research with translational potential and to create new portfolio companies.

JLABS, Tuesday Morning, Feb. 6, 2018

Topic: "The Art and Science of Productive FDA Meetings"

Speaker: Ron Farkas, MD PhD, Vice President, Technical, PAREXEL Consulting
Tuesday, February 6, 2018 from 10:30 AM to 1:00 PM (PST)

Agenda:

10:30 AM | Registration & Networking

11:00 AM | Presentation

11:40 AM | Q&A

12:00 PM | Networking Lunch

1:00 PM | Program Close

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, CA

Fees:

\$25 | General Public

\$10 | Student/Academic

\$35 | At the door

Details and registration at <https://www.eventbrite.com/e/the-art-and-science-of-productive-fda-meetings-tickets-37017978771?aff=weekly>

Event Details

Getting solutions to patients can be a long and complicated process. Working with the FDA is a key part of the sequence. Preparing for and understanding the FDA's needs is essential to smooth the way and shorten your time to approval.

Johnson & Johnson Innovation, JLABS is happy to be hosting Ron Farkas, MD PhD, Vice President, Technical, PAREXEL Consulting, to discuss the ins and outs of FDA meetings. Ron will pull from his vast experience which includes a decade plus run at the FDA to help guide us through these vital interactions. Topics will include:

Understanding the FDA's position; not just what it wants but why

What to agree on now and later; What does agreement mean?

The key to proceed

Understanding the dynamics within the FDA
Flexibility and norms and what they mean
Experts, Patients and Advocates at Meetings
Meeting minutes and follow up

Understanding the process will help you better prepare for your meetings and build confidence in and ability to adjust your own plan. Come prepared with your questions!

Speaker Bio

Ron Farkas | Vice President, Technical, PAREXEL Consulting

Dr. Ronald Farkas is a senior regulatory professional with over 15 years of experience in all phases of drug development from preclinical development through marketing application, advisory committee meetings, labeling negotiations, and the post-approval period. Dr. Farkas has in-depth cross-disciplinary expertise in clinical safety and efficacy, clinical pharmacology and pharmacogenomics, preclinical development, statistical analysis, and biomarker/surrogate endpoint development and utilization.

Dr. Farkas uses his extensive scientific, drug development and regulatory experience to assist clients in negotiating with regulatory authorities across the entire product life cycle to achieve their company objectives.

Prior to joining PAREXEL, Dr. Farkas was a Cross-Disciplinary Team Leader at FDA in CDER's Division of Neurology Products, with prior assignments to the Office of New Drugs Guidance and Policy Team and the CDRH Office of Device Evaluation. Prior to joining the FDA, Dr. Farkas was an assistant professor and attending surgeon at the Johns Hopkins University Wilmer Ophthalmic Institute.

Dr. Farkas completed residency training in ophthalmology at the Harvard University School of Medicine Massachusetts Eye and Ear Infirmary, subsequent to earning dual MD and PhD degrees in neuroanatomy and neuropharmacology from the University of Illinois at Chicago School of Medicine.

JLABS, Thursday Mid Day, March 29, 2018

Event: Meet With... Frazier Healthcare Partners

Speakers: James W. Brush, M.D. | Senior Associate, Frazier Healthcare Partners and Patrick Heron, MBA | Managing General Partner, Frazier Healthcare Partners

Date and Time: Thursday, March 29, 2018 from 10:30 AM to 1:00 PM (PDT)

Agenda:

10:30AM | Registration and Networking

11:00 AM | Presentation and Q&A

12:00 PM | Networking Lunch

1:00-5:15 PM | One-on-One Meeting* (30 - minute meetings)

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due February 22,, 2018. Apply Here.

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Apply to meet one-on-one with Jamie Brush of Frazier Healthcare Partners. Your application will be reviewed and you will be notified of acceptance on March 13th. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Details and registration at <https://www.eventbrite.com/e/meet-with-frazier-healthcare-partners-tickets-36705859213?aff=weekly>

Event Description

With over 26 years of exclusively investing in over 170 healthcare companies, Frazier Healthcare Partners has a great deal of experience building successful life science businesses. On March 29, 2018, Jamie Brush MD, and Patrick Heron, MBA will be visiting JLABS @ SSF to provide an overview of Frazier Healthcare Partners' unique investment strategies and meet 1-on-1 with pre-selected companies.

*The one-on-one application process is separate from the event registration process. Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due by February 22nd. Apply Here.

Program Overview:

Frazier Healthcare Partners is committed to helping great healthcare companies who are working hard to make a difference in the future of life sciences. The firm has partnered with exceptional entrepreneurs at all stages and focuses on therapeutic development. With \$3 billion under management, investments in over 170 companies and 35 IPOs, Frazier Healthcare Partners has built a team with deep knowledge and scientific expertise that enables company building.

Jamie Brush, MD and Patrick Heron, MBA will be in attendance to provide an overview presentation of the firm's areas of interest. They will be on hand to meet with a handful of applicants 1-on-1 after the presentation. To be considered for a 1-on-1 meeting, please complete the information required here. Applications due by Feb 22, 2018.

Speakers' Biographies:

James W. Brush, M.D. | Senior Associate, Frazier Healthcare Partners

Jamie joined Frazier Healthcare Partners in 2016 and focuses on investment identification, due diligence, and deal closing.

Before joining Frazier, Jamie was a management consultant with the Boston Consulting Group, where he was a core member of the Healthcare Practice. In this capacity, he led projects involving Biotechnology mergers and acquisitions, R&D, manufacturing and business development strategy.

Jamie received his M.D. from the University of Southern California, where he was inducted into Alpha Omega Alpha honors society, and his B.A. from Middlebury College. He completed his postgraduate training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston. He has co-authored several papers in top-tier journals on genomic instability and its role in cancer, and is a member of the board of directors of Longwood Symphony Orchestra.

Patrick Heron, MBA | Managing General Partner, Frazier Healthcare Partners

Patrick is a Managing General Partner of Frazier's Life Sciences team. He joined the firm in 1999 and opened Frazier's Menlo Park office in 2003. Throughout his 12 years as General Partner, Patrick has led or co-led investments across nearly 20 companies.

Patrick has successfully partnered with entrepreneurs across a range of company types and stages, from early – stage anti-infectives companies to >\$100M commercial-stage dermatology companies. Patrick has also been active in company formation around both early – and later – stage assets. He has led and served as director for many successful Frazier Life Sciences investments, including Tobira Therapeutics (acquired by Valeant), MedPointe (acquired by Meda), and Collegium (NASDAQ: COLL). He currently serves on the boards of Imago BioSciences, Iterum Therapeutics, Silvergate Pharmaceuticals, SutroVax and Zavante Therapeutics.

Prior to joining Frazier, Patrick helped develop McKinsey & Company's West Coast biotechnology consulting practices, where he led projects involving mergers and acquisitions, product launches, sales force optimization, corporate partnering, and research prioritization.

Patrick received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar.